CRISPR Therapeutics (NASDAQ: CRSP) CFO covers RSU taxes with share sale and gift

Rhea-AI Filing Summary

CRISPR Therapeutics AG Chief Financial Officer Prasad Raju exercised and vested restricted stock units and related common shares, then disposed of a portion mainly for tax obligations and a gift. On March 14, 2026, he acquired 16,875 common shares through the conversion of restricted stock units granted in 2023 and 2025. On March 16, 2026, 9,869 common shares were sold at $48.26 per share to satisfy tax withholding requirements under the company’s RSU Settlement Policy, and 750 shares were transferred as a bona fide gift without consideration. After these transactions, he directly held 13,023 common shares, which remain subject to a lock-up related to the company’s convertible senior notes due 2031.

Insights

Equity compensation analyst

Routine RSU vesting with tax sales and a gift; limited signal.

The transactions show CRISPR Therapeutics CFO Prasad Raju converting restricted stock units into 16,875 common shares, consistent with multi-year vesting schedules from awards granted in 2023 and 2025. This is standard equity compensation, not an open-market purchase.

On March 16, 2026, 9,869 common shares were sold at $48.26 per share. Footnote language explains these sales were mandated to cover tax withholding obligations under the company’s RSU Settlement Policy, rather than discretionary trading. A further 750 shares were transferred as a bona fide gift with no consideration.

Following these moves, Raju directly holds 13,023 common shares, which remain subject to a lock-up tied to convertible senior notes due 2031. Because the dispositions are largely tax- and gift-related, with no remaining derivative position reported, the overall signal for investors is routine and not thesis-changing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Prasad Raju

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MA 02127

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/14/2026		M(1)		10,000	A	(2)	16,767	D
Common Shares	03/14/2026		M(1)		6,875	A	(2)	23,642	D
Common Shares	03/16/2026		S		5,848(3)	D	$48.26	17,794	D
Common Shares	03/16/2026		S		4,021(3)	D	$48.26	13,773	D
Common Shares	03/16/2026		G(4)		750	D	$0.00	13,023	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/14/2026		M(1)			10,000	(5)	(5)	Common Shares	10,000	(2)	10,000	D
Restricted Stock Units	(2)	03/14/2026		M(1)			6,875	(6)	(6)	Common Shares	6,875	(2)	20,625	D

Explanation of Responses:

1. These shares remain subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031.

2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

3. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.

4. Reporting person remains subject to a lock-up agreement with the underwriters of the Issuer's offering of convertible senior notes due 2031. Transfers of lock-up securities as a bona fide gift are permitted. No consideration was received by the reporting person in connection with such transfer.

5. This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027.

6. This restricted stock unit award was granted on March 14, 2025 with respect to 27,500 Common Shares, with (i) one quarter of the shares vesting on March 14, 2026, (ii) one quarter of the shares vesting on March 14, 2027, (iii) one quarter of the shares vesting on March 14, 2028, and (iv) one quarter of the shares vesting on March 14, 2029.

	Elizabeth Ryland Waldinger, attorney-in-fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did CRISPR Therapeutics (CRSP) CFO Prasad Raju do in this Form 4?

The filing shows CFO Prasad Raju exercised restricted stock units into 16,875 common shares, then sold 9,869 shares and gifted 750 shares. These actions support RSU vesting, tax withholding, and a bona fide gift, rather than discretionary trading activity.

How many CRISPR Therapeutics (CRSP) shares did the CFO sell and at what price?

Prasad Raju sold 9,869 CRISPR Therapeutics common shares at an average price of $48.26 per share. According to the disclosure, these sales were executed to cover tax withholding obligations arising from restricted stock unit vesting under the company’s RSU Settlement Policy.

Were the CRSP CFO’s share sales discretionary or related to taxes?

The filing states the sold shares were required to satisfy tax withholding obligations from restricted stock unit vesting. It specifies this sale is mandated by CRISPR Therapeutics’ RSU Settlement Policy and “does not represent a discretionary trade” by CFO Prasad Raju, reducing its informational trading signal.

How many CRISPR Therapeutics (CRSP) shares does the CFO own after these transactions?

After the reported transactions, CFO Prasad Raju directly holds 13,023 CRISPR Therapeutics common shares. The disclosure notes these remaining shares are still subject to a lock-up agreement associated with the company’s offering of convertible senior notes due 2031, limiting certain transfers.

What restricted stock unit awards are vesting for the CRSP CFO?

One restricted stock unit award, granted in March 2023 for 40,000 shares, vests in four equal annual installments from 2024 to 2027. Another, granted in March 2025 for 27,500 shares, vests annually from 2026 through 2029, driving future share deliveries.

Did the CRISPR Therapeutics (CRSP) CFO make a gift of shares?

Yes. The filing reports a bona fide gift of 750 CRISPR Therapeutics common shares. Footnotes explain that such transfers are permitted under the existing lock-up agreement and that CFO Prasad Raju received no consideration in connection with the gifted shares.